2.05
2.05 (0%)
As of Feb 14, 2025
Tscan Therapeutics, Inc. [TCRX]
Source:
Company Overview
Tscan Therapeutics, Inc is a clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer.
| Country | United States |
| Headquarters | waltham, massachusetts |
| Phone Number | 857-399-9500 |
| Industry | |
| CEO | Gavin Macbeath |
| Website | https://www.tscan.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $2.8 |
| Operating Profit | $-134.8 |
| Net Income | $-127.5 |
| Net Cash | $45.3 |
Profit Ratios
| Gross Margin | $2.8 |
| Operating Margin | -4,787.7 |
| Profit as % of Revenues | -2.2% |
| Profit as % of Assets | -39.6% |
| Profit as % of Stockholder Equity | -52.9% |
Management Effectiveness
| Return on Equity | -52.9% |
| Return on Assets | -34.4% |
| Turnover Ratio | 0.9% |
| EBITA | $-134.8 |
Balance Sheet and Cash Flow Measures
| Total Assets | $371.1 |
| Total Liabilities | $130.1 |
| Operating Cash Flow | $-110.8 |
| Investing Cash Flow | $-52.6 |
| Financing Cash Flow | $208.8 |
